Zevra Therapeutics drug Miplyffa is now FDA approved for Niemann-Pick disease type C, a lysosomal storage disorder. The affirmative regulatory decision took into account additional clinical data generated since the FDA turned down a submission for the drug in 2021.
The post FDA Approval Makes a Zevra Drug the First Therapy for Rare and Fatal Metabolic Disease appeared first on MedCity News.
